Review
New dosing schedules of dasatinib for CML and adverse event management
-
Correspondence: Siu-Fun Wong siuwong@westernu.edu
Western University of Health Sciences, College of Pharmacy, Pomona, CA, USA
Journal of Hematology & Oncology 2009, 2:10 doi:10.1186/1756-8722-2-10
Published: 23 February 2009Additional files
Additional File 1:
Wong Tables 1–4. The data provided in these tables are varied: Table 1 describes agents that may interact with dasatinib; Table 2 describes the efficacy data for dasatinib from a large phase II trial program; Table 3 and 4 provide management recommendations for cytopenias and non-hematologic AEs, respectively.
Format: DOC Size: 81KB Download file
This file can be viewed with: Microsoft Word Viewer
